Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Return on Assets (2020 - 2025)

Historic Return on Assets for Innate Pharma (IPHYF) over the last 6 years, with Q2 2025 value amounting to 0.95%.

  • Innate Pharma's Return on Assets fell 7700.0% to 0.95% in Q2 2025 from the same period last year, while for Jun 2025 it was 0.95%, marking a year-over-year decrease of 7700.0%. This contributed to the annual value of 0.0% for FY2022, which is 200.0% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Return on Assets is 0.95%, which was down 7700.0% from 0.57% recorded in Q4 2024.
  • Innate Pharma's Return on Assets' 5-year high stood at 0.0% during Q4 2022, with a 5-year trough of 0.95% in Q2 2025.
  • Its 5-year average for Return on Assets is 0.28%, with a median of 0.25% in 2022.
  • In the last 5 years, Innate Pharma's Return on Assets skyrocketed by 2500bps in 2022 and then plummeted by -7700bps in 2025.
  • Innate Pharma's Return on Assets (Quarter) stood at 0.26% in 2021, then surged by 99bps to 0.0% in 2022, then plummeted by -657bps to 0.03% in 2023, then crashed by -1950bps to 0.57% in 2024, then tumbled by -67bps to 0.95% in 2025.
  • Its Return on Assets stands at 0.95% for Q2 2025, versus 0.57% for Q4 2024 and 0.18% for Q2 2024.